Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 110

1.

Silybin supplementation during HCV therapy with pegylated interferon-α plus ribavirin reduces depression and anxiety and increases work ability.

Malaguarnera G, Bertino G, Chisari G, Motta M, Vecchio M, Vacante M, Caraci F, Greco C, Drago F, Nunnari G, Malaguarnera M.

BMC Psychiatry. 2016 Nov 15;16(1):398.

2.

Resveratrol in Hepatitis C Patients Treated with Pegylated-Interferon-α-2b and Ribavirin Reduces Sleep Disturbance.

Pennisi M, Bertino G, Gagliano C, Malaguarnera M, Bella R, Borzì AM, Madeddu R, Drago F, Malaguarnera G.

Nutrients. 2017 Aug 18;9(8). pii: E897. doi: 10.3390/nu9080897.

3.

Silybin-vitamin E-phospholipids complex reduces liver fibrosis in patients with chronic hepatitis C treated with pegylated interferon α and ribavirin.

Malaguarnera M, Motta M, Vacante M, Malaguarnera G, Caraci F, Nunnari G, Gagliano C, Greco C, Chisari G, Drago F, Bertino G.

Am J Transl Res. 2015 Nov 15;7(11):2510-8. eCollection 2015.

4.

Low Efficacy of Pegylated Interferon plus Ribavirin plus Nitazoxanide for HCV Genotype 4 and HIV Coinfection.

Macías J, López-Cortés LF, Téllez F, Recio E, Ojeda-Burgos G, Ríos MJ, Rivero-Juárez A, Delgado M, Rivas-Jeremías, Pineda JA.

PLoS One. 2015 Dec 7;10(12):e0143492. doi: 10.1371/journal.pone.0143492. eCollection 2015.

5.
6.

Sustained virological response to pegylated interferon plus ribavirin leads to normalization of liver stiffness in hepatitis C virus-infected patients.

Macías J, Rivero A, Cifuentes C, Camacho A, Neukam K, Rivero-Juárez A, Mira JA, Torre-Cisneros J, Gómez-Mateos J, Pineda JA.

Enferm Infecc Microbiol Clin. 2013 Aug-Sep;31(7):424-9. doi: 10.1016/j.eimc.2012.12.004. Epub 2013 Feb 28.

PMID:
23453582
7.

[Depressive symptoms during treatment with interferon alpha for HCV infection--preliminary report].

Małyszczak K, Inglot M, Pawłowski T, Czarnecki M, Rymer W, Andrzej K.

Psychiatr Pol. 2006 Jul-Aug;40(4):799-808. Polish.

PMID:
17068951
8.

Merimepodib, pegylated interferon, and ribavirin in genotype 1 chronic hepatitis C pegylated interferon and ribavirin nonresponders.

Rustgi VK, Lee WM, Lawitz E, Gordon SC, Afdhal N, Poordad F, Bonkovsky HL, Bengtsson L, Chandorkar G, Harding M, McNair L, Aalyson M, Alam J, Kauffman R, Gharakhanian S, McHutchison JG; MErimepodib TRiple cOmbination Study Group.

Hepatology. 2009 Dec;50(6):1719-26. doi: 10.1002/hep.23204.

PMID:
19852040
9.

Retreatment of hepatitis C patients with pegylated interferon combined with ribavirin in non-responders to interferon plus ribavirin. Is it different in real life?

Gonçales FL Jr, Moma CA, Vigani AG, Angerami AF, Gonçales ES, Tozzo R, Pavan MH, Gonçales NS.

BMC Infect Dis. 2010 Jul 20;10:212. doi: 10.1186/1471-2334-10-212.

10.

Pegylated interferon-alpha, ribavirin, and rituximab combined therapy of hepatitis C virus-related mixed cryoglobulinemia: a long-term study.

Dammacco F, Tucci FA, Lauletta G, Gatti P, De Re V, Conteduca V, Sansonno S, Russi S, Mariggiò MA, Chironna M, Sansonno D.

Blood. 2010 Jul 22;116(3):343-53. doi: 10.1182/blood-2009-10-245878. Epub 2010 Mar 22.

PMID:
20308602
11.

Therapeutic effectiveness of biosimilar standard interferon versus pegylated interferon for chronic hepatitis C genotypes 2 or 3.

Vigani AG, Gonçales ES, Pavan MH, Genari F, Tozzo R, Lazarini MS, Fais V, Feltrin A, Gonçales NS, Gonçales FL Jr.

Braz J Infect Dis. 2012 May-Jun;16(3):232-6.

12.

Response of hepatitis C genotype-4 naïve patients to 24 weeks of Peg-interferon-alpha2b/ribavirin or induction-dose interferon-alpha2b/ribavirin/amantadine: a non-randomized controlled study.

El-Zayadi AR, Attia M, Barakat EM, Badran HM, Hamdy H, El-Tawil A, El-Nakeeb A, Selim O, Saied A.

Am J Gastroenterol. 2005 Nov;100(11):2447-52.

PMID:
16279899
13.

Effects of PEG-interferon alpha plus ribavirin on tryptophan metabolism in patients with chronic hepatitis C.

Comai S, Cavalletto L, Chemello L, Bernardinello E, Ragazzi E, Costa CV, Bertazzo A.

Pharmacol Res. 2011 Jan;63(1):85-92. doi: 10.1016/j.phrs.2010.10.009. Epub 2010 Oct 19.

PMID:
20940053
14.

A randomized controlled trial of pegylated interferon alpha-2a (40 KD) or interferon alpha-2a plus ribavirin and amantadine vs interferon alpha-2a and ribavirin in treatment-naïve patients with chronic hepatitis C.

Mangia A, Ricci GL, Persico M, Minerva N, Carretta V, Bacca D, Cela M, Piattelli M, Annese M, Maio G, Conte D, Guadagnino V, Pazienza V, Festi D, Spirito F, Andriulli A.

J Viral Hepat. 2005 May;12(3):292-9.

PMID:
15850470
15.

Open, randomized, multicentre italian trial on PEG-IFN plus ribavirin versus PEG-IFN monotherapy for chronic hepatitis C in HIV-coinfected patients on HAART.

Cargnel A, Angeli E, Mainini A, Gubertini G, Giorgi R, Schiavini M, Duca P; Italian Co-infection Study (ICOS) Group.

Antivir Ther. 2005;10(2):309-17.

PMID:
15865225
16.

Effect of aging, glucose level, and HIV viral load on response to treatment with pegylated interferon plus ribavirin in HIV/HCV co-infected women.

Nasta P, Maida I, Cattelan AM, Pontali E, Angeli E, Giralda M, Verucchi G, Caputo A, Iannacone C, Puoti M, Carosi G.

J Womens Health (Larchmt). 2015 Feb;24(2):159-64. doi: 10.1089/jwh.2014.4796. Epub 2015 Feb 3.

PMID:
25682817
17.

A randomized trial of pegylated interferon alpha-2b plus ribavirin in the retreatment of chronic hepatitis C.

Jacobson IM, Gonzalez SA, Ahmed F, Lebovics E, Min AD, Bodenheimer HC Jr, Esposito SP, Brown RS Jr, Bräu N, Klion FM, Tobias H, Bini EJ, Brodsky N, Cerulli MA, Aytaman A, Gardner PW, Geders JM, Spivack JE, Rahmin MG, Berman DH, Ehrlich J, Russo MW, Chait M, Rovner D, Edlin BR.

Am J Gastroenterol. 2005 Nov;100(11):2453-62.

PMID:
16279900
18.

Role of baseline depressive symptoms in the development of depressive episode in patients receiving antiviral therapy for hepatitis C infection.

Mahajan S, Avasthi A, Grover S, Chawla YK.

J Psychosom Res. 2014 Aug;77(2):109-15. doi: 10.1016/j.jpsychores.2014.05.008. Epub 2014 Jun 2.

PMID:
25077851
19.

Predictive value of early virological response to treatment with different interferon-based regimens plus ribavirin in patients with chronic hepatitis C.

Napoli N, Giannelli G, Parisi CV, Antonaci A, Maddalena G, Antonaci S.

New Microbiol. 2005 Jan;28(1):13-21.

PMID:
15782622

Supplemental Content

Support Center